The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
机构：[1]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[2]Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[3]Department of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[4]Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China[5]Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China[6]Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China[7]Department of Thoracic Medical Oncology, Jilin Cancer Hospital, Changchun, China[8]Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China[9]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China[10]Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China[11]Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China[12]Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China[13]Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[14]Department of Respiratory Diseases, Tang Du Hospital, Xi’an, China[15]First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China[16]Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China[17]Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan[18]Division of Medical Oncology, London Regional Cancer Program at London Health Science Center, London, Canada[19]Schulich School of Medicine and Dentistry at Western University, London, Canada[20]Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan[21]Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan[22]Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA[23]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Anlotinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with non-small cell lung cancer (NSCLC) in the ALTER0303 trial. The status of epidermal growth factor receptor (EGFR) mutation, different previous treatment may affect the efficacy of subsequent therapy, and we did this subgroup analysis to characterize the efficacy of anlotinib in patients with and without EGFR mutation.The ALTER0303 trial was a randomized, double-blind, phase 3 study of anlotinib in patients with NSCLC who failed at least 2 lines of treatment. In the study, 138 of 437 randomized patients were EGFR mutation positive. A Cox model was used to examine the influence of previous treatment on the efficacy of anlotinib according to EGFR mutation status.For patients with EGFR mutation, the OS was 10.7 and 6.3 months (HR 0.59; 95% CI: 0.38-0.94, P=0.025) in the anlotinib and placebo group, respectively. The PFS was 5.6 and 0.8 months (HR 0.21; 95% CI: 0.13-0.32, P<0.0001) in the anlotinib and placebo group, respectively. For patients without EGFR mutation, the OS was 8.9 months for anlotinib and 6.5 months for placebo (HR 0.73; 95% CI: 0.55-0.97, P=0.029), and the PFS was 5.4 months for anlotinib and 1.6 months for placebo (HR 0.29; 95% CI: 0.22-0.39, P<0.0001). In the anlotinib group, the OS and PFS for patients with and without EGFR mutation was 10.7 and 8.9 months (HR 0.69; 95% CI: 0.50-0.95, P=0.021), 5.6 and 5.4 months (HR 1.00; 95% CI: 0.75-1.34, P=1.000), respectively. The incidence of adverse events was similar in subgroups.This analysis demonstrated that the benefit of anlotinib as a third-line therapy for patients with NSCLC was independent of EGFR mutation status.2022 Translational Lung Cancer Research. All rights reserved.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区呼吸系统4 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学3 区呼吸系统
第一作者：
第一作者机构：[1]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
通讯作者：
通讯机构：[1]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China[23]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[*1]Shanghai Chest Hospital, West Huaihai Road, No. 241 Xuhui Distinct, Shanghai 200030, China[*2]Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, Tianjin 300060, China
推荐引用方式(GB/T 7714)：
Yizhuo Zhao,Qiming Wang,Li Zhang,et al.The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study[J].Translational lung cancer research.2022,11(5):776-785.doi:10.21037/tlcr-22-320.
APA：
Yizhuo Zhao,Qiming Wang,Li Zhang,Jianhua Shi,Zhehai Wang...&Baohui Han.(2022).The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.Translational lung cancer research,11,(5)
MLA：
Yizhuo Zhao,et al."The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study".Translational lung cancer research 11..5(2022):776-785
